Cover Image

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial

Show other versions (1)

BACKGROUND: To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer. - METHODS: In this prospective phase II trial, patients with HER2-negative metastatic breast cancer received first-line capecitabine 2000 mg/m(2) on day...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaufmann, Manfred (Author) , Maass, Nicolai (Author) , Costa, Serban-Dan (Author) , Schneeweiss, Andreas (Author) , Loibl, Sibylle (Author) , Sütterlin, Marc (Author) , Schrader, Iris (Author) , Gerber, Bernd (Author) , Bauer, Wolfgang (Author) , Wiest, Wolfgang (Author) , Tomé, Oliver (Author) , Distelrath, Andrea (Author) , Hagen, Volker (Author) , Kleine-Tebbe, Anke (Author) , Ruckhäberle, Eugen (Author) , Mehta, Keyur (Author) , Minckwitz, Gunter von (Author)
Format: Article (Journal)
Language:English
Published: 2010 Aug 24
In: European journal of cancer
Year: 2010, Volume: 46, Issue: 18, Pages: 3184-3191
ISSN:1879-0852
Online Access: Get full text
Author Notes:M. Kaufmann, N. Maass, S.D. Costa, A. Schneeweiss, S. Loibl, M. W. Sütterlin, I. Schrader, B. Gerber, W. Bauer, W. Wiest, O. Tomé, A. Distelrath, V. Hagen, A. Kleine-Tebbe, E. Ruckhaeberle, K. Mehta, G. von Minckwitz, for the GBG-39 trialists
Search Result 1
Cover Image

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial by Kaufmann, Manfred (Author) , Maass, Nicolai (Author) , Costa, Serban-Dan (Author) ,


Get full text
Article (Journal)

Saved in:
Show all versions (2)

Similar Items